Twitter Updates

    follow me on Twitter

    Friday, April 15, 2011


    The FDA sent out a nationwide announcement about "the potential side effects of osteoporosis drugs like Fosamax [alendronate]." the agency "said in their announcement...physicians need to watch for the possibility of possible risk of femur fractures. And this didn't just apply to Fosamax, this applied to all four drugs that are in this group Fosamax, Actonel [risedronate], Boniva [ibandronate], and Reclast [zoledronic acid]."

    Studies show the bones of some post-menopausal women who take ward off osteoporosis can stop rejuvenating and become brittle after long-term use." Researchers found that "the drugs are effective initially in slowing bone loss," but "the quality of the bone diminished after long-tern bisphosphonate use." A separate study indicated that "bone densitometry (DXA) scans show a buckling potential in the femur area of the hip in patients being treated for osteoporosis with bisphosphonates."

    The FDA is now examining whether long-term use of the drugs increases the risk of atypical subtrochanteric femur fractures, but so far, the agency said the data it "has reviewed have not shown a clear connection."

    Please remember, as with all our articles we provide information, not medical advice. For any treatment of your own medical condition you must visit your local doctor, with or without our article[s]. These articles are not to be taken as individual medical advice.

    Deepen your understanding of "medical malpractice"...

    For more health info and links visit the author's web site

    No comments:

    Post a Comment